
USD
+$0.00
(+0.00%
)At Close (As of Dec 11, 2025)
$1.86B
Market Cap
-
P/E Ratio
-0.13
EPS
$51.13
52 Week High
$20.85
52 Week Low
HEALTHCARE
Sector
| Field | Value (USD) |
|---|---|
| Gross Profit | $150M |
| Total Revenue | $200M |
| Cost Of Revenue | $49M |
| Costof Goods And Services Sold | $49M |
| Operating Income | $8.8M |
| Selling General And Administrative | $129M |
| Research And Development | $12M |
| Operating Expenses | $142M |
| Investment Income Net | - |
| Net Interest Income | -$23M |
| Interest Income | - |
| Interest Expense | $23M |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $13M |
| Income Before Tax | -$17M |
| Income Tax Expense | $161K |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | -$17M |
| Comprehensive Income Net Of Tax | - |
| Ebit | $9.1M |
| Ebitda | $22M |
| Net Income | -$17M |
| Field | Value (USD) |
|---|---|
| Total Assets | $389M |
| Total Current Assets | $190M |
| Cash And Cash Equivalents At Carrying Value | $47M |
| Cash And Short Term Investments | $47M |
| Inventory | $11M |
| Current Net Receivables | $117M |
| Total Non Current Assets | $199M |
| Property Plant Equipment | - |
| Accumulated Depreciation Amortization Ppe | - |
| Intangible Assets | $187M |
| Intangible Assets Excluding Goodwill | $187M |
| Goodwill | $332K |
| Investments | - |
| Long Term Investments | - |
| Short Term Investments | $3.4M |
| Other Current Assets | $15M |
| Other Non Current Assets | - |
| Total Liabilities | $320M |
| Total Current Liabilities | $91M |
| Current Accounts Payable | $39M |
| Deferred Revenue | - |
| Current Debt | - |
| Short Term Debt | $497K |
| Total Non Current Liabilities | $228M |
| Capital Lease Obligations | $9.3M |
| Long Term Debt | $220M |
| Current Long Term Debt | - |
| Long Term Debt Noncurrent | - |
| Short Long Term Debt Total | $229M |
| Other Current Liabilities | $52M |
| Other Non Current Liabilities | - |
| Total Shareholder Equity | $70M |
| Treasury Stock | - |
| Retained Earnings | -$151M |
| Common Stock | $35K |
| Common Stock Shares Outstanding | $36M |
| Field | Value (USD) |
|---|---|
| Gross Profit | $150M |
| Total Revenue | $200M |
| Cost Of Revenue | $49M |
| Costof Goods And Services Sold | $49M |
| Operating Income | $8.8M |
| Selling General And Administrative | $129M |
| Research And Development | $12M |
| Operating Expenses | $142M |
| Investment Income Net | - |
| Net Interest Income | -$23M |
| Interest Income | - |
| Interest Expense | $23M |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $13M |
| Income Before Tax | -$17M |
| Income Tax Expense | $161K |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | -$17M |
| Comprehensive Income Net Of Tax | - |
| Ebit | $9.1M |
| Ebitda | $22M |
| Net Income | -$17M |
Sector: HEALTHCARE
Industry: DRUG MANUFACTURERS - SPECIALTY & GENERIC
Harrow Health, Inc. is a prominent healthcare company based in San Diego, California, focused on the development and commercialization of cutting-edge ophthalmic products. The firm leverages its proprietary formulations and advanced drug delivery technologies to improve patient outcomes for a range of ocular conditions and surgical needs. With a robust portfolio of FDA-approved products, Harrow Health is well-positioned to capitalize on the growing demand for sophisticated eye care solutions in the expanding ophthalmology sector. Driven by a commitment to innovation and improving patient care, the company aspires to be a transformative force in global eye health.